We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Completed
2
66.7%
Suspended
1
33.3%
No approval data available
- Medincell launched a private placement representing approximately 6% of share capital to international institutional investors through an accelerated book-building process. - The French biopharmaceutical company plans to use proceeds to expand partnering opportunities, maximize collaboration value, and strengthen its proprietary long-acting injectable technology platform. - UZEDY, the company's first commercialized product using BEPO technology, generated $191 million in U.S. net sales in 2025 with Teva projecting $250-280 million for 2026. - The FDA accepted Teva's New Drug Application for Olanzapine LAI in February 2026, following submission in December 2025, with EU regulatory filing expected in Q2 2026.
